

Substituted 1,1-Diphenyl-3-aminoprop-1-enes and 1,1-Diphenyl-3-aminopropanes as Potential Antidepressant Agents


G. JONES, R. F. MAISEY,* A. R. SOMERVILLE, AND B. A. WHITTLE

Imperial Chemical Industries Limited, Pharmaceuticals Division, Alderley Park, Macclesfield, Cheshire, England

Received April 13, 1970


A series of substituted 1,1-diphenyl-3-aminoprop-1-enes and 1,1-diphenyl-3-aminopropanes has been prepared. These compounds display interesting properties as potential antidepressant agents.

The observation of antireserpine activity of a low order in compounds of the general structure I¹ and the structural relationship of these compounds to known antidepressant drugs, such as amitriptyline (II) and imipramine (III), led us to investigate the pharmacological properties of compounds of the general structures IV and V. 1,1-Diphenyl-3-aminoprop-1-enes (IV) and 1,1-diphenyl-3-aminopropanes (V) have previously been examined as potential analgetics,² antihistamines,³ antispasmodics,^{3,4} and analeptics.⁵ This paper is concerned with the synthesis of new compounds of the generic structures IV and V and their evaluation as potential antidepressants.



Chemistry.—The 1,1-diphenyl-3-aminoprop-1-enes IV were prepared in most cases by the methods illustrated below. The amino alcohols VII in which $\text{R}^1 = \text{R}^2$ were prepared best by reaction of a Grignard reagent with the appropriate ethyl β -aminopropionate derivative VI (route A). The alternative reaction of a Grignard reagent with a Mannich base VIII (route B) generally gave inferior yields, probably on account of enolization of the Mannich base.⁶

Dehydration of amino alcohols VII in which the aromatic rings have different substituents ($\text{R}^1 \neq \text{R}^2$) gave rise to mixtures of the geometrical isomers of the corresponding 1,1-diphenyl-3-aminoprop-1-enes. It was evident from the nmr spectra of these products that the geometrical isomers were generally formed in about equal proportions. Isomeric mixtures were tested as such in the form of either the HCl or oxalate salt.



Primary 1,1-diphenyl-3-aminoprop-1-enes (IV, $\text{R}^3 = \text{R}^4 = \text{H}$) were prepared by LAH reduction of the corresponding unsaturated nitriles (route C). When this reaction was carried out in Et_2O at room temp reduction of the conjugated double bond was significant, but at -20° reduction of the nitrile was not accompanied by reduction of the double bond.

1,1-Diphenyl-3-aminopropanes (V) were prepared by catalytic hydrogenation of the corresponding 1,1-diphenyl-3-aminoprop-1-enes (IV) or, in the case of secondary amines (V, $\text{R}^3 = \text{H}$), by hydrogenolysis of the corresponding 1,1-diphenyl-3-benzylaminoprop-1-enes (IV, $\text{R}^3 = \text{CH}_2\text{C}_6\text{H}_5$).

Structure-Activity Relationships.—The more active members of this series, *e.g.*, **6**, **16**, and **17**, have activities comparable with those of known clinically effective antidepressants such as amitriptyline or imipramine, and some, particularly the monomethylamino compounds, *e.g.*, **5**, **15**, and **18**, are more active in the pharmacological and biochemical tests reported.

In the olefinic series substitution in the Ph rings with halogen, especially F, marginally improves the

(*) To whom inquiries should be addressed.

(1) Unpublished observation from this laboratory.

(2) P. A. J. Janssen, "Synthetic Analgesics," Part 1, Pergamon Press, London, 1960.


(3) A. C. White, A. F. Green, and A. Hudson, *Brit. J. Pharmacol.*, **6**, 560 (1951).

(4) P. V. Petersen, *Acta Pharmacol. Toxicol.*, **7**, 51 (1951).

(5) K. Zipf, *Arzneimitt.-Forsch.*, **13**, 166 (1963).

(6) R. Baltzly and J. W. Billingham, *J. Org. Chem.*, **30**, 4330 (1965).

TABLE I



	R ¹	R ²	R ³	R ⁴	Method	Yield, ^a %	Mp of HCl or oxalate, °C	Formula ^f	Reversal of reserpine- induced hypothermia ED ₅₀ , mg/kg	% inhi- bition of 5-HT uptake at 10 μg/ml	Oral acute LD ₅₀ (mice) mg/kg
1	H	H	H	H	C	70	214-216	C ₁₅ H ₁₅ N ^b	>100		
2	2-CH ₃	H	H	H	C	70	186-188	C ₁₈ H ₁₉ ClN	100		
3	2-F	H	H	H	C	50	180-182	C ₁₅ H ₁₃ ClFN	100		
4	4-F	H	H	H	C	48	189-190	C ₁₅ H ₁₃ ClFN	100		
5	H	H	CH ₃	H	B	43	147-148	C ₁₈ H ₁₉ ClN ^b	1	96	201
6	H	H	CH ₃	CH ₃	A or B		168-170	C ₁₇ H ₂₀ ClN ^b	1.5	88	271
7	H	H	CH ₃	C ₂ H ₅	c	84	155-157 (ox)	C ₂₀ H ₂₃ NO ₄	1-3		
8	H	H	(CH ₃) ₂ CH	H	d	21	144-146	C ₁₈ H ₂₂ ClN	>100		
9	H	H	C ₂ H ₅	C ₂ H ₅	A or B		146-147	C ₁₉ H ₂₄ ClN ^b	30-100		
10	H	H	CH ₂ CH=CH ₂	H	A	60	146-147	C ₁₈ H ₂₀ ClN	100		
11	H	H			A		165-167	C ₁₉ H ₂₂ ClN ^b	100		
12	H	H			A		209-210	C ₂₀ H ₂₄ ClN ^b	100		
13	H	H			A		218-219	C ₁₉ H ₂₂ ClNO ^b	100		
14	H	H			A	75	195-200	C ₂₀ H ₂₆ Cl ₂ N ₂ ^b	100		
15	4-F	H	CH ₃	H	B	22	136-140	C ₁₈ H ₁₇ ClFN	0.6	96	177
16	4-F	H	CH ₃	CH ₃	B	10	188-190	C ₁₇ H ₁₉ ClFN	0.6	81	225
17	3-F	H	CH ₃	CH ₃	B	31	144-148	C ₁₇ H ₁₉ ClFN	0.5	78	352
18	4-Cl	H	CH ₃	H	B	12	140-142	C ₁₈ H ₁₇ Cl ₂ N	0.7	98	110
19	4-Cl	H	CH ₃	CH ₃	B	12	210-212	C ₁₇ H ₁₉ Cl ₂ N	3	64	~400
20	4-Br	H	CH ₃	CH ₃	B	35	170-171	C ₁₇ H ₁₉ BrClN	0.6		180
21	3-CF ₃	H	CH ₃	CH ₃	B	45	175-179	C ₁₈ H ₁₉ ClF ₃ N	3		118
22	2-CH ₃	H	CH ₃	H	B	20	156-160	C ₁₇ H ₂₀ ClN	15		281
23	2-CH ₃	H	CH ₃	CH ₃	B	18	192-194	C ₁₈ H ₂₂ ClN	15		609
24	2-CH ₃ O	H	CH ₃	CH ₃	B	41	172-175	C ₁₈ H ₂₂ ClNO	8		284
25	4-F	4-F	CH ₃	H	A	13	215-216 (ox)	C ₁₈ H ₁₇ F ₂ NO ₄	3	97	
26	4-F	4-F	CH ₃	CH ₃	A	37	211-213	C ₁₇ H ₁₈ ClF ₂ N	3	74	287
27	4-F	4-F	CH ₃	CH ₂ C ₆ H ₅	A	33	130-132	C ₂₃ H ₂₂ ClF ₂ N	10-30		
28	3-F	3-F	CH ₃	H	A	31	177-179	C ₁₈ H ₁₈ ClF ₂ N	2	99	<200
29	3-F	3-F	CH ₃	CH ₃	A	32	156-159	C ₁₇ H ₁₈ ClF ₂ N	2	66	164
30	3-CF ₃	3-CF ₃	CH ₃	CH ₃	A	47	158-160	C ₁₉ H ₁₈ ClF ₃ N	100		
31	4-Cl	4-Cl	CH ₃	H	A	10	216-219 (ox)	C ₁₈ H ₁₇ Cl ₂ NO ₄	2	94	472
32	4-Cl	4-Cl	CH ₃	CH ₃	B	40	230-232	C ₁₇ H ₁₈ Cl ₂ N	3	48	615
33	4-Cl	4-Cl	CH ₃	CH ₂ C ₆ H ₅	A	38	185-187	C ₂₃ H ₂₂ Cl ₂ N	60		
34	4-Cl	4-F	CH ₃	CH ₃	B	18	194-196	C ₁₇ H ₁₈ Cl ₂ FN	100	73	
35	4-Cl	3-F	CH ₃	CH ₃	B	20	145-147	C ₁₇ H ₁₈ Cl ₂ FN	4	67	409
36	4-Cl	2-CH ₃ O	CH ₃	CH ₃	B	25	156-159	C ₁₈ H ₂₁ Cl ₂ NO	7		
37	(e)	H	CH ₃	CH ₃	B	22	147-150	C ₁₅ H ₁₅ ClNS ^b	10		
	Amitriptyline								3	92	420
	Imipramine								7	94	680
	Desimipramine								0.8-1.6	92	
	Nortriptyline								1.0-2.0	94	

^a Overall yield for both stages based on ester (A) or Mannich base·HCl (B). ^b Described in the literature. ^c Reduction of N-Ac derivative with LAH. See ref 12. ^d Reductive alkylation of amino compd with NaBH₄ and Me₂CO. See ref 12. ^e Ph replaced by thienyl. ^f All compounds, except those with footnote b, were analyzed for C, H, N.

activity; other substituents are usually dystherapeutic. High activity is retained only in compounds in which N is substituted with either N and Me or two Me radicals, the secondary amines being markedly superior in their ability to inhibit the uptake of 5-HT by human platelets. Substitution of the CH₂ adjacent to N with Me or substitution of the olefinic H with Me diminishes the activity. Replacement of propenyl by a butenyl skeleton is, unexpectedly in view of the amitriptyline structure II, dystherapeutic.

The saturated compounds are in general marginally less active, but with this reservation the same relationships hold as for the unsaturated series.

Experimental Section

Pharmacology. Test Methods.—The potential antidepressant activity of the test compounds was assessed by their ability

to antagonize reserpine-induced hypothermia⁷ in mice. In the case of the more active members of the series this test was supplemented by a detn of the compds' capacity to inhibit the uptake of 5-HT into human platelets.⁸ The limitations of these tests in the prediction of clinically useful antidepressant activity are well known and have been documented.⁹⁻¹¹ One to four groups of 6 mice per treatment were given reserpine (2 mg of base/kg sc as the phosphate). Seventeen hours later the temp of the mice (*T*₀) was recorded, and the animals were dosed orally with the antidepressant treatment or saline. The temps (*T*₂, *T*₄, and *T*₆) were again recorded at intervals of 2, 4, and 6 hr. Gastric temps were measured by means of an orally inserted probe and displayed on an electric thermometer (type 3G10, Light Labo-

(7) J.-R. Boissier, J. Fichelle-Pagny, P. Simon, *Therapie*, **21**, 109 (1966).

(8) A. Todrick, A. C. Tait, *J. Pharm. Pharmacol.*, **21**, 751 (1969).

(9) L. Gyermek, *Int. Rev. Neurobiol.*, **9**, 95 (1966).

(10) L. J. Hekimian, S. Gershon, and A. Floyd, *Curr. Therapeutic Res.*, **10**, 282 (1968).


(11) S. Gershon, L. J. Hekimian, and A. Floyd, *Arzneimitt.-Forsch.*, **18**, 243 (1968).

TABLE II

		Yield, ^a %	Mp of HCl, °C	Formula ^c	Reversal of reserpine-induced hypothermia ED ₁₀ , mg/kg
38	Ph ₂ C=C(CH ₃)CH ₂ NMe ₂	26	188-190	C ₁₃ H ₂₂ ClN ^b	>30
39	2-MePh C=CCH ₂ NMe ₂ Ph CH ₃	29	181-182	C ₁₉ H ₂₄ ClN ^b	30
40	2-MeOPh C=CHCHNMe ₂ Ph CH ₃	30	148-150	C ₁₉ H ₂₄ ClNO	>100
41	Ph ₂ C=CH(CH ₂) ₂ NMe ₂	20	180-182	C ₁₃ H ₂₂ ClN ^b	>100
42	Ph ₂ C=CHCHNMe ₂ CH ₃	12	158-161	C ₁₃ H ₂₂ ClN ^b	

^a Comps 38-42 were prepd from PhMgBr and the corresponding aminoacetone followed by dehydration of the aminocarbinal. The overall yield is based upon the aminoacetone. ^b Described in the literature. ^c See footnote f, Table I.

TABLE III



	R ¹	R ²	R ³	R ⁴	Yield, %	Mp of HCl or oxalate, °C	Formula ^a	Reversal of reserpine-induced hypothermia ED ₁₀ , mg/kg	% inhibition of 2-HT uptake ^a 10 μg/ml ^t
43	H	H	CH ₃	H			C ₁₆ H ₂₀ ClN ^b		
44	H	H	CH ₃	CH ₃	78	169-170	C ₁₇ H ₂₂ ClN ^b	3	87
45	3-F	H	CH ₃	CH ₃	69	166-168	C ₁₇ H ₂₁ ClFN	2	
46	4-F	H	CH ₃	CH ₃	80	141-144	C ₁₇ H ₂₁ ClFN	3	
47	4-Cl	H	CH ₃	CH ₃	70	155-157	C ₁₇ H ₂₁ Cl ₂ N	50	90
48	3-CF ₃	H	CH ₃	CH ₃	76	145-148	C ₁₈ H ₂₁ ClF ₃ N	8.5	
49	2-Me	H	CH ₃	CH ₃	86	164-166	C ₁₅ H ₂₄ ClN	20	
50	2-MeO	H	CH ₃	CH ₃	86	166-167	C ₁₈ H ₂₄ ClNO	15	
51	3-F	3-F	CH ₃	CH ₃	87	178-180	C ₁₇ H ₂₀ ClF ₂ N	2	
52	4-F	4-F	CH ₃	CH ₃	86	188-189	C ₁₇ H ₂₀ ClF ₂ N	10	81
53	3-CF ₃	3-CF ₃	CH ₃	CH ₃	77	198-200 (ox)	C ₂₁ H ₂₁ F ₆ NO ₄	100	
54	4-Cl	4-Cl	CH ₃	CH ₃	62	190-194	C ₁₇ H ₂₀ Cl ₂ N	50	
55	4-F	4-Cl	CH ₃	CH ₃	85	173-176	C ₁₇ H ₂₀ Cl ₂ FN ^c	100	
56	4-F	4-F	CH ₃	H	75	188-192 (ox)	C ₁₈ H ₁₉ F ₂ NO ₄	10	97
57	4-Cl	4-Cl	CH ₃	H	63	212-214 (ox)	C ₁₈ H ₁₉ Cl ₂ NO ₄		
58	H	H				135-136	C ₁₉ H ₂₄ ClN ^b	10-30	
59	H	H				215-217	C ₂₀ H ₂₆ ClN ^b	>100	
60	H	H				208-209	C ₁₉ H ₂₄ ClNO ^b	>100	

^a See footnote f, Table I. ^b Previously described. ^c N anal. only.

ratories, Brighton, England) which was read to an accuracy of $\pm 0.05^\circ$. The effect of the compound was computed from the mean cumulative rise in temp at the intervals T_2 , T_4 , and T_6 . The mean cumulative rise is thus defined as: $\Delta^\circ C = T_2 + T_4 + T_6 - 3T_0$.

The hyperthermic effect was related to dose and, using suitable doses, a dose of drug could be defined which gave a cumulative rise in temp of 10° greater than controls, thus yielding the ED₁₀ values recorded in Tables I, II, and III.

The inhibition of the uptake of 5-HT in platelets was detd as follows. A suspension of human platelets in saline was preincubated with drug for 5 min before adding ¹⁴C-labeled 5-HT. After incubation for a further 20 min the suspension was chilled and filtered through a Millipore filter. The filter was washed and transferred to a vial of dioxan naphthalene-phosphor for counting. The radioactivity of the platelets is a measure of the uptake of 5-HT. The percentage inhibition produced by drugs as com-

pared with saline-treated controls is recorded in Tables I and III.¹²

Logarithmically spaced doses of compd were administered orally to groups of 5-10 mice, and the percentage mortality at day 7 was detd by inspection. LD₅₀'s were computed by standard logit analysis, but results for selected compounds were tabulated.

N-Substituted ethyl β-aminopropionates (IV) were prepd by mixing equimolar proportions of the appropriate secondary or tertiary amine and ethyl acrylate and fractionally distg the product.¹³

Mannich base hydrochlorides (V) were prepd by standard methods from the appropriately substituted acetophenones.

N-Substituted 3-Amino-1,1-diphenylpropan-1-ols (VI).—The

(12) Full details will be published by A. R. Somerville in *Eur. J. Pharmacol.*

(13) D. W. Adamson, *J. Chem. Soc.*, S144, (1949).

general methods employed are illustrated for symmetrically or unsymmetrically substituted carbinolamines by the following 2 examples.

1,1-Di-(4-fluorophenyl)-3-dimethylaminopropan-1-ol.—A soln of 29.0 g (0.2 mole) of ethyl β -dimethylaminopropionate in 50 ml of anhyd Et₂O was added gradually with stirring to a cooled (0°) Et₂O soln of a Grignard reagent prep'd from 105 g (0.6 mole) of *p*-BrC₆H₄F and 14.6 g (0.6 mole) of Mg. After stirring in the cold for 1 hr and then refluxing for 2 hr, the cooled mixture was decomp'd with 200 ml of a 10% w/v soln of NH₄Cl. Basification with NH₄OH and extraction with CHCl₃ (3 × 250 ml) afforded a CHCl₃ soln which on drying and evapn gave 58.0 g of a crude oil. This crude product was dehydrated without further purification.

3-Dimethylamino-1-(4-fluorophenyl)-1-phenylpropan-1-ol.— β -Dimethylaminopropiophenone·HCl (21.4 g, 0.1 mole) was added portionwise to a cooled (0°), stirred Et₂O soln of the Grignard reagent prepared from 35 g (0.2 mole) of *p*-BrC₆H₄F and 4.8 g (0.2 mole) of Mg. After stirring in the cold for 1 hr and then refluxing for 2 hr, the cooled mixture was decomp'd and worked up as above. The crude colorless solid (11 g) was dehydrated without further purification.

1,1-Di-(4-fluorophenyl)-3-dimethylaminoprop-1-ene (25).—A soln of 41.0 g (0.14 mole) of the carbinolamine in 250 ml of AcOH and 80 ml of conc'd HCl was refluxed for 30 min. The soln was conc'd under reduced pressure, dild with H₂O, and basified with NH₄OH. The base was extracted Et₂O, and Et₂O soln was dried

and evap'd. Distn under reduced pressure gave 20.5 g of an oil. The base was converted into its hydrochloride in anhyd Et₂O. Crystn of the hydrochloride from EtOAc–EtOH gave an anal. sample, mp 211–213°.

1,1-Di-(4-fluorophenyl)-3-dimethylaminopropane (53).—A soln of 5 g of the olefin·HCl in 20 ml of EtOH was hydrogenated at atm temp and pressure using 2.5 g of 5% Pd–C. After 1 mole of H₂ had been absorbed, the catalyst was filtered, the soln was conc'd, and the product was ppt'd with Et₂O. Filtration gave 3.0 g of material. Crystn from EtOAc–EtOH gave an anal. sample, mp 188–189°.

1,1-Diphenylprop-1-enylamine (1).—Diethyl phosphonoacetate (106 g) was added dropwise to a stirred suspension of NaH (15 g) in dry dimethoxyethane (500 ml) at 0°. The mixture was stirred for 1 hr after the evoln of H₂ ceased, and a soln of benzophenone (91 g) in dimethoxyethane (100 ml) was then added dropwise. The mixture was stirred at 20° for 2 hr, then poured into H₂O (2000 ml), and extracted (Et₂O). Evapn and distn of the extract gave β,β -diphenylacrylonitrile (63 g, mp 48–49°). This (60 g) was added dropwise to a stirred soln of LAH (20 g) in dry Et₂O (500 ml) at –20°. The mixture was stirred for 2 hr at –20° and for 15 min at 0°. Excess LAH was destroyed by addn of H₂O, and the organic phase was sepd, dried (MgSO₄), and evap'd. 1,1-Diphenylprop-1-enylamine (1) was isolated from the residual oil as its hydrochloride (58 g, mp 206–208°) by addn of ethereal HCl. The hydrochloride, recryst'd from EtOH–Et₂O, had mp 214–216°.

Notes

Synthesis of 3-Trifluoromethyl Steroids^{1a}

ABRAHAM F. PASCUAL^{1b} AND MANFRED E. WOLFF^{1c*}

*Department of Pharmaceutical Chemistry,
School of Pharmacy, University of California,
San Francisco, California 94122*

Received July 28, 1970

The function of the carbonyl moiety of C-3 of steroid hormones in eliciting the biological response has been the subject of intensive study in this laboratory. Among C-2 and/or C-3 substituted steroids prepared to test the possibility that π bonding,² high electron density, or H bonding² might be important in terms of steroid–receptor interaction have been steroidal cyclopropanes² and nitro derivatives.³ In the present study, the preparation of steroidal C-3 substituted CF₃ derivatives was undertaken, inasmuch as CF₃ represents a center which is both electron rich and capable of H bonding.

The introduction of a CF₃ group by photochemical addition of CF₃I across a double bond has been applied to 3 β -ethoxy-17 β -hydroxypregna-3,5-dien-20-one ace-

tate⁴ but such reactions with unconjugated olefinic steroids have not been reported. In the present study, several methods were tried in preparing the 3-CF₃ steroids. Attempted conversion of a 3-CO₂H substituent into a 3-CF₃ group by reaction with SF₄⁴ failed. Likewise, reaction of a 3-keto steroid, dihydrotestosterone acetate, with F₃CMgI⁵ yielded only starting material. Finally, employing a modified method of Godfredsen and Vangedal,⁶ the 3-CF₃ steroid derivative was obtained.

A solution of 5 α -pregn-3-en-20-one (**1**) in CCl₄, CF₃I, and a small amount of pyridine was irradiated with uv light for 8 hr under N₂. Only one product, 3 α -trifluoromethyl-4 β -iodo-5 α -pregn-20-one (**2**), was isolated from the reaction mixture although 8 isomeric adducts (4 cis and 4 trans) could be formed from this reaction. The stereochemistry of **2** was established from further reactions as shown in Scheme I and from the nmr spectra of the adduct and its derivatives.

The C-19 Me peak of **2** was shifted 0.36 ppm downfield compared with **1** and upon hydrogenolysis of the iodo group with LAH, the C-19 Me resonance shifted 0.33 ppm upfield. As it is well known that electro-negative groups produce a deshielding effect (0.25 ppm) on the C-19 Me group when they are in a 1:3 diaxial

* Address correspondence to this author.

(1) (a) This investigation was supported in part by a Public Health Service Research Grant AM-05016 from the National Institute of Arthritis and Metabolic Diseases, U. S. Public Health Service. (b) Taken from a part of the Ph.D. Thesis of A. F. Pascual, University of California, San Francisco, Calif., 1969. (c) It is a pleasure to acknowledge the contribution made to this work by Barbara Rehermann Vicente who carried out preliminary studies on the photolysis reaction as part of her M.S. research.

(2) M. E. Wolff, W. Ho, and R. Kwok, *J. Med. Chem.*, **7**, 577 (1964).

(3) M. E. Wolff and R. C. Boguslaski, *ibid.*, **11**, 285 (1968).

(4) (a) W. R. Hasek, W. C. Smith, and V. A. Engelhardt, *J. Amer. Chem. Soc.*, **82**, 543 (1960). (b) D. G. Martin and F. Kagan, *J. Org. Chem.*, **27**, 3164 (1962).

(5) (a) R. N. Haszeldine, *J. Chem. Soc.*, 1273 (1954). (b) E. T. McBee, R. D. Battershell, and H. P. Braedndliin, *J. Org. Chem.*, **28**, 1131 (1963).

(6) W. Godfredsen and S. Vangedal, *Acta Chim. Scand.*, **15**, 1768 (1961).